Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- HC Wainwright & Co. analyst Mitchell S. Kapoor downgraded Summit Therapeutics Inc (NASDAQ:SMMT) from Buy to Neutral. Summit Therapeutics shares closed at $17.47 on Thursday. See how other analysts view this stock.
- JP Morgan analyst Puneet Jain downgraded Endava PLC – ADR (NYSE:DAVA) from Neutral to Underweight and lowered the price target from $9 to $5. Endava shares closed at $3.34 on Thursday. See how other analysts view this stock.
Considering buying SMMT stock? Here’s what analysts think:
Photo via Shutterstock
Login to comment